<DOC>
	<DOCNO>NCT02376699</DOCNO>
	<brief_summary>This study examine safety profile SEA-CD40 . The study test increase dos SEA-CD40 give least every 3 week small group patient . The goal find high dose SEA-CD40 give patient cause unacceptable side effect . Different dose regimen may also evaluate see SEA-CD40 give within treatment cycle maintain acceptable safety profile . The pharmacokinetics , pharmacodynamic effect , biomarkers response , antitumor activity SEA-CD40 also evaluate .</brief_summary>
	<brief_title>Safety Study SEA-CD40 Cancer Patients</brief_title>
	<detailed_description>The study conduct follow part : Part A : Dose-regimen finding solid tumor -- Dose-escalation , possible dose-interval modification lengthen treatment cycle , define maximum tolerate dose ( MTD ) and/or optimal biological dose ( OBD ) regimens patient solid tumor . The ability increase dose intensity ( give additional dos within treatment cycle ) may evaluate . Part B : Solid tumor expansion cohort -- Disease-specific solid tumor expansion cohort may enrol patient treated dos MTD and/or OBD determine Part A . Part C : Dose-regimen finding lymphoma -- Dose-escalation , possible dose-interval modification lengthen treatment cycle , define MTD and/or OBD regimens patient lymphoma . The ability increase dose intensity ( give additional dos within treatment cycle ) may evaluate . Part D : Lymphoma expansion cohort -- Disease-specific lymphoma expansion cohort may enrol patient treated dos MTD and/or OBD determine Part C .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>Histologically confirm advanced malignancy , either : ( ) Metastatic unresectable solid malignancy ; ( b ) Classical Hodgkin lymphoma ( HL ) , diffuse large Bcell lymphoma ( DLBCL ) , indolent lymphoma ( include follicular lymphoma [ FL ] ) Relapsed , refractory , progressive disease , specifically : ( ) Solid tumor : Following least 1 prior systemic therapy , standard therapy available patient 's advanced solid tumor time enrollment ; ( b ) Classical HL : Following least 2 prior systemic therapy patient candidate autologous stem cell transplant ( SCT ) , follow failure autologous SCT ; ( c ) DLBCL : Following least 1 prior systemic therapy ; patient must also receive intensive salvage therapy unless refuse deem ineligible ; ( ) Indolent lymphoma : Following least 1 prior chemoimmunotherapy regimen include antiCD20 monoclonal antibody appropriate treatment option exist Representative baseline tumor tissue sample available Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate baseline hematologic , renal , hepatic function Recovery Grade 1 clinically significant toxicity prior initiation study drug administration Prior chemotherapy , small molecule inhibitor , radiation , and/or investigational anticancer agent ( exclude investigational monoclonal antibody ) within 2 week Prior immunecheckpoint inhibitor within 4 week Prior monoclonal antibody , antibodydrug conjugate , radioimmunoconjugates within 4 week ( 2 week patient experience disease progression prior treatment ) Prior Tcell cellbased therapy within 12 week ( 2 week patient experience disease progression prior treatment ) Recent ongoing serious infection within 2 week Active autoimmune autoinflammatory ocular disease within 6 month Known suspect active organthreatening autoimmune disease Prior current central nervous system tumor metastases Patients lymphoma : prior allogeneic SCT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CD40 Antigen</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Indolent Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>Solid tumor</keyword>
</DOC>